Biomarkers of Alzheimer's disease (AD), including fluid and imaging biomarkers of amyloid and tau pathology, have enabled a better understanding of AD pathophysiology, facilitated clinical trials that have led to the development of amyloid-lowering treatments, and increased the accuracy of clinical dementia diagnosis1. The gene discussed is MAPT; the disease is Alzheimer disease.